SES
15.7.2021 08:52:09 CEST | Business Wire | Press release
Communities living across the eastern most peninsula of Africa will be able to enjoy 4G services on their mobile phones following a three-year partnership agreement signed by fixed satellite solution and professional service provider, iSAT Africa and SES, the leader in global content connectivity solutions. The two companies announced today that this new service will be available first via SES’s O3b medium earth orbit (MEO) constellation to subsequently migrate and expanded to SES’s next-generation MEO system, O3b mPOWER, in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005981/en/
iSAT Africa is well-established in the region for embracing innovative mobile internet connectivity solutions for unconnected rural communities in Africa. Through SES’s highly-flexible and scalable O3b mPOWER system that can deliver low-latency high-speed connectivity services from tens of megabits to multiple gigabits per second to a single site, iSAT Africa will be able to quickly scale its network to meet anticipated extensive connectivity demands. The fibre-like connectivity will equipe iSAT Africa to enable local mobile operators to deploy 4G services to close the digital divide. iSAT Africa is among the first companies in Africa to sign up for O3b mPOWER.
According to the GSMA 2020 report, mobile coverage has been expanding in Sub-Saharan Africa quickly; 3G coverage expanded to 75% compared to 63% in 2017, while 4G doubled to nearly 50% compared to 2017. However, the coverage gap in Sub-Saharan Africa remains the highest globally as it is home to 67% of the world’s population not covered by mobile broadband. This is because attempts to deploy 4G networks in sparsely-populated rural and remote areas continue to be an economic challenge. With telcos and internet service providers increasingly seeking innovative, cost-effective yet reliable connectivity solutions, SES’s MEO satellite-based MEF-certified service that can ensure seamless interconnectivity with any network is an ideal solution.
“At iSAT Africa, we don’t just believe in delivering connectivity to everyone across Africa. It’s also about delivering differentiated, cost-effective and reliable services that will enable various businesses to expand. This agreement represents a leap towards achieving that mission with iSAT Africa being able to deliver 4G services to communities and businesses located in underserved areas. As long-term partners of SES, we are confident this innovative solution will enable us to offer differentiated connectivity services to our telco customers,” said Rakesh Kukreja, Founder and Managing Director at iSAT Africa.
John-Paul Hemingway, CEO of SES Networks said, “We will be able to revolutionise the connectivity capabilities of mobile operators across Africa together through this agreement with iSAT Africa. The O3b and O3b mPOWER systems will easily enable the deployment of 4G services and high-performance networks for cloud applications regardless of where they are across the region. The enhanced flexibility and scalability of O3b mPOWER will truly connect Africans living in underserved areas in the most economically viable manner.”
Follow us on:
Twitter , Facebook , YouTube , LinkedIn , Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About iSAT Africa
iSAT Africa, a fast-growing communication service provider in Africa and Middle East, is a UAE based company whose mission is to transform the way Africa gets and stays connected with the rest of the world. iSAT’s unique connectivity solutions deliver efficiency, reliability and affordability for Data, Internet, Voice and Video solutions . These customized solutions serve broadcast and media organizations, multinationals, major ISPs, Governmental and Non-Governmental organizations as well as Tier 1 telecom operators.
With its network of partners and service providers, iSAT Africa is able to satisfactorily deliver end-to-end solutions, turn-key solutions and managed services to it’s customers/ partners within the shortest time possible whilst adhering to agreed upon service level agreements.
iSAT’s Satellite Solutions, backed by powerful satellites, teleport and data infrastructure, latest technologies and inhouse human expertise is very unique in the industry. It is against this background that iSAT Africa partners with other leaders within the telco space in a bid to adequately meet its customers ever growing demand for telecommunication services across the African continent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005981/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom